NDA 214581 · Novitium Pharma
Sovuna
Hydroxychloroquine Sulfate · Oral
Last checked: Nov 20, 2026Latest source record: Oct 10, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Jan 14, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
544
162 Phase 3, 62 recruiting
FAERS reports
40,482
35,382 serious, 4,537 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 8, 2024.
SOVUNA is an antimalarial and antirheumatic indicated for the: Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax in adult and pediatric patients. (1.1) Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported in adult and pediatric patients. (1.1) Treatment of rheumatoid arthritis in adults. (1.2) Treatment of systemic lupus erythematosus in adults. (1.3) Treatment of chronic discoid lupus erythematosus in adults. (1.4) Limitations of Use (1.1): SOVUNA is not recommended for the: Treatment of complicated malaria. Treatment of chloroquine or hydroxychloroquine-resistant strains of Plasmodium species. Treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. Prophylaxis of malaria in geographic areas where chloroquine resistance occurs. Prevention of relapses of P. vivax or P. ovale because it is not active against the hypnozoite liver stage forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline drug is necessary. 1.1 Malaria SOVUNA is indicated in adult and pediatric patients for the: Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax, and Plasmodium ovale. Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use: SOVUNA is not recommended for: Treatment of complicated malaria. Treatment of malaria by chloroquine or hydroxychloroquine-resistant strains of Plasmodium species [see Microbiology (12.4)]. Treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium...
Mechanism: Malaria Hydroxychloroquine is a 4-aminoquinoline antimalarial [see Microbiology (12.4)] and antirheumatic agent. Rheumatoid Arthritis, Systemic Lupus Erythematosus and Chronic Discoid Lupus Erythematosus The mechanisms underlying the anti-inflammatory and immunomodulatory effects of SOVUNA in the treatment of rheumatoid arthritis, chronic discoid lupus erythematosus and systemic lupus erythematosus are not fully known.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- SOVUNA · HYDROXYCHLOROQUINE SULFATE 200MG · TABLET, ORAL · Prescription
- SOVUNA · HYDROXYCHLOROQUINE SULFATE 300MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Hydroxychloroquine" as an intervention, any sponsor and status, largest first.
- Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)Pivotal-lookingStatus unknown
Kafrelsheikh UniversityAcademic, hospital or other
NCT04353180 · 100,000 participants (planned) · Start Aug 2021 · Primary completion Oct 2021
Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment; Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment and 3 more · For: COVID19
Sites: Cairo, Egypt · 2 sites in all
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare SettingPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT04303507 · 4,652 participants · Start Apr 29, 2020 · Primary completion Mar 22, 2022
Drug: Chloroquine or Hydroxychloroquine; Placebo · For: COVID19; Coronavirus; Acute Respiratory Illnesses
Sites: Abomey-Calavi, Benin; Allada, Benin; Abidjan, Côte d’Ivoire · 25 sites in all
- A Preventive Treatment for Migrant Workers at High-risk of COVID-19Pivotal-lookingCompleted
National University Hospital, SingaporeAcademic, hospital or other
NCT04446104 · 4,257 participants · Start May 13, 2020 · Primary completion Aug 31, 2020
Drug: Hydroxychloroquine Sulfate Tablets; Ivermectin 3mg Tab and 2 more · For: Covid-19
Sites: Singapore, Singapore
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)Pivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT05041907 · 3,800 participants (planned) · Start Sep 30, 2021 · Primary completion Jan 2027
Drug: Nirmatrelvir/ritonavir (e.g. PAXLOVID™); Nitazoxanide and 16 more · For: COVID-19
Sites: Minas Gerais, Brazil; Vientiane, Laos; Kathmandu, Nepal · 7 sites in all
- Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as PreventionPivotal-lookingCompleted
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaAcademic, hospital or other
NCT04304053 · 2,300 participants · Start Mar 18, 2020 · Primary completion Jun 15, 2020
Drug: Treatment and prophylaxis · For: COVID-19
Sites: Barcelona, Spain
- An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core StudiesPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00720798 · 2,067 participants · Start Sep 2005 · Primary completion Apr 2013
Drug: Tocilizumab; Disease-modifying anti-rheumatic drugs and 2 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Mesa, Arizona · 295 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective18,316
- rheumatoid arthritis13,898
- pain10,999
- fatigue9,608
- drug intolerance9,402
- off label use8,673
- arthralgia8,566
- joint swelling8,555
- contraindicated product administered8,205
- alopecia7,852
- abdominal discomfort7,845
- rash7,825
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 173 |
| 2005 | 231 |
| 2006 | 174 |
| 2007 | 243 |
| 2008 | 402 |
| 2009 | 368 |
| 2010 | 660 |
| 2011 | 421 |
| 2012 | 723 |
| 2013 | 208 |
| 2014 | 143 |
| 2015 | 370 |
| 2016 | 904 |
| 2017 | 1,044 |
| 2018 | 1,597 |
| 2019 | 3,281 |
| 2020 | 7,825 |
| 2021 | 5,384 |
| 2022 | 4,541 |
| 2023 | 2,948 |
| 2024 | 3,572 |
| 2025 | 3,390 |
| 2026 | 1,880 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sovuna (Hydroxychloroquine Sulfate)
2024 spending
$25K
Beneficiaries
19
30 claims
Per beneficiary
$1,305
$16.02 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $24,802 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- [Not Available].
Soto A, Quiñones-Laveriano DM, Garcia PJ, et al. · Rev Peru Med Exp Salud Publica 2020 · Multicenter Study, Randomized Controlled Trial
- Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis.
Chu AWL, Oykhman P, Chu X, et al. · J Allergy Clin Immunol 2025 · Comparative Study, Network Meta-Analysis
- Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Horby P, Mafham M, Linsell L, et al. · N Engl J Med 2020 · Comparative Study, Multicenter Study
- Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers.
Izmirly P, Kim M, Friedman DM, et al. · J Am Coll Cardiol 2020 · Clinical Trial, Phase II, Multicenter Study
- Mycophenolate Mofetil and New-Onset Systemic Lupus Erythematosus: A Randomized Clinical Trial.
You Y, Zhou Z, Wang F, et al. · JAMA Netw Open 2024 · Randomized Controlled Trial, Multicenter Study
- Ototoxic effects of hydroxychloroquine.
Gonçalves LF, Patatt FSA, de Paiva KM, et al. · Rev Assoc Med Bras (1992) 2021 · Systematic Review
Sponsor: Novitium Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.